Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies

NCT00804076 is registered in ClinicalTrials.gov with Diamyd Inc as lead sponsor.

NCT NCT00804076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00804076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies
Lead sponsor
Diamyd Inc
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
July 31, 2013
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer pain